Which hedge funds own ADPT? ADAPTIVE BIOTECHNOLOGIES COR, Q2 2026 13F holders
Healthcare · Open on the interactive board
9 of the hedge funds tracked by WhaleCreep disclosed a position in ADPT (ADAPTIVE BIOTECHNOLOGIES COR) in their Q2 2026 13F filings, worth $784.8m in total. The largest holder by portfolio weight is Viking Global Investors at 1.8% of its book. 3 exited: Brevan Howard Capital Management, Farallon Capital Management, Point72 Asset Management LP.
9tracked managers holding
0opened this quarter
3exited this quarter
Which hedge funds hold ADPT? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Viking Global Investors | Q2 2026 | 1.8% | $643.4m | 29,993,708 | 0% | held |
| D. E. Shaw & Co | Q2 2026 | 0.1% | $99.2m | 4,625,859 | 135% | added |
| Tudor Investment | Q2 2026 | 0.0% | $11.7m | 543,485 | -31% | reduced |
| Polen Capital Management | Q2 2026 | 0.0% | $2.2m | 102,457 | -12% | reduced |
| Renaissance Technologies LLC | Q2 2026 | 0.0% | $6.5m | 302,800 | 26% | added |
| Millennium Management | Q2 2026 | 0.0% | $10.8m | 504,909 | -53% | reduced |
| Marshall Wace | Q2 2026 | 0.0% | $6.3m | 292,079 | 238% | added |
| Bridgewater Associates | Q2 2026 | 0.0% | $859.9k | 40,087 | -55% | reduced |
| Citadel Advisors | Q2 2026 | 0.0% | $3.9m | 181,356 | -50% | reduced |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Brevan Howard Capital Management | 0.2% | $2.4m |
| Farallon Capital Management | 0.0% | $152.7k |
| Point72 Asset Management LP | 0.3% | $14.2m |
Held in a manager's last filing on record
These managers have not filed for the latest quarter; their last disclosure is dated.
| Manager | Last filing | Weight |
|---|---|---|
| Caxton Associates | Q4 2024 | 0.0% |
How has hedge fund ownership of ADPT changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 9 | $784.8m |
| Q1 2026 | 12 | $498.7m |
| Q4 2025 | 6 | $509.2m |
| Q3 2025 | 6 | $474.6m |
| Q2 2025 | 7 | $451.5m |
| Q1 2025 | 4 | $324.9m |
| Q4 2024 | 6 | $277.8m |
| Q3 2024 | 5 | $233.3m |
| Q2 2024 | 4 | $161.7m |
| Q1 2024 | 5 | $131.2m |
| Q4 2023 | 3 | $179.2m |
| Q3 2023 | 3 | $194.9m |
| Q2 2023 | 3 | $206.9m |
| Q1 2023 | 4 | $272.7m |
| Q4 2022 | 3 | $240.0m |
| Q3 2022 | 5 | $225.9m |
Counts every tracked manager that disclosed ADPT in that quarter's filing, including managers that have since stopped filing.